News | 08 August 2021
Cipla posts net profit at Rs 715 crores
India business contributes to a stellar performance
India business contributes to a stellar performance
Forex gains stood at Rs 20 crore for the quarter
Ibuprofen and Famotidine Tablets is an AB-rated generic therapeutic equivalent version of Horizon Medicines LLC’s Duexis Tablets, 800 mg/26.6 mg
This robust growth has come despite the raging pandemic for most part of the quarter
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
Dr.Reddy's will receive U.S. $6 million upfront upon closing followed by U.S. $9 million one year from closing
The company has been consistently reducing debt
It had an estimated market size of US $ 32 million as of June 2021
EPS climbs to Rs 9.25 for the quarter
It is part of the company’s pain/analgesics portfolio of OTC products
Arrow is the marketing partner in US
Aditya Puri former MD of HDFC bank joins Solara board as chairman
Robust demand for the product across the Middle East, Africa and Latin America
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
India business is growing as per projections; whereas US business will bounce back soon.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Turnover of API division of ISLL stood at Rs 856.58 crore
Subscribe To Our Newsletter & Stay Updated
